DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Bekaii-Saab T, Ou FS, Anderson DM, Ahn D, Boland P, Ciombor K. et al.
Regorafenib dose optimization study (ReDOS): Randomized phase II trial to evaluate dosing strategies for regorafenib in refractory metastatic colorectal cancer (mCRC)—an ACCRU Network study ASCO GI abstract 611.
J Clin Oncol 2018:36(Suppl 4S)
We do not assume any responsibility for the contents of the web pages of other providers.